Therapeutic Potential of Targeting Prokineticin Receptors in Diseases

• Published in: Pharmacological reviews Vol. 75; no. 6; pp. 1167 - 1199
• Main Authors: Vincenzi, Martina, Kremić, Amin, Jouve, Appoline, Lattanzi, Roberta, Miele, Rossella, Benharouga, Mohamed, Alfaidy, Nadia, Migrenne-Li, Stephanie, Kanthasamy, Anumantha G., Porcionatto, Marimelia, Ferrara, Napoleone, Tetko, Igor V., Désaubry, Laurent, Nebigil, Canan G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2023; American Society for Pharmacology and Experimental Therapeutics; The American Society for Pharmacology and Experimental Therapeutics
• Subjects: Biomarkers; Humans; Life Sciences; Neoplasms - drug therapy; Neuropeptides - metabolism; Peptides; Pharmaceutical sciences; Receptors, G-Protein-Coupled - metabolism; Review; AMPA; IHH; PVN; Aβ; −; ECs; Th; TRPV 1; TBI; AgRP; AVITG; MI; AD; IL; HCC; DOX; MAPK; RA; PKR; Bmal-1; EAT; GPCR; NH2; Acsl4; MET; CFA; EG-VEGF; MAT; Bv8; CNS; T. cruzi; CFP; SNI; OA; OB; OD; dpc; NPY; SVZ; COOH; GnRH; BMI; CCI; KS; AKT; ECL; EDPC; ICL; PC; PD; Ca2; ONs; PE; DRG; Tcf21; RMS; TM; ATM; PK; MRAP2; HF; SCN; TS
• ISSN: 0031-6997; 1521-0081; 1521-0081
• DOI: 10.1124/pharmrev.122.000801

The prokineticins (PKs) were discovered approximately 20 years ago as small peptides inducing gut contractility. Today, they are established as angiogenic, anorectic, and proinflammatory cytokines, chemokines, hormones, and neuropeptides involved in variety of physiologic and pathophysiological pathways. Their altered expression or mutations implicated in several diseases make them a potential biomarker. Their G-protein coupled receptors, PKR1 and PKR2, have divergent roles that can be therapeutic target for treatment of cardiovascular, metabolic, and neural diseases as well as pain and cancer. This article reviews and summarizes our current knowledge of PK family functions from development of heart and brain to regulation of homeostasis in health and diseases. Finally, the review summarizes the established roles of the endogenous peptides, synthetic peptides and the selective ligands of PKR1 and PKR2, and nonpeptide orthostatic and allosteric modulator of the receptors in preclinical disease models. The present review emphasizes the ambiguous aspects and gaps in our knowledge of functions of PKR ligands and elucidates future perspectives for PK research. This review provides an in-depth view of the prokineticin family and PK receptors that can be active without their endogenous ligand and exhibits “constitutive” activity in diseases. Their non- peptide ligands display promising effects in several preclinical disease models. PKs can be the diagnostic biomarker of several diseases. A thorough understanding of the role of prokineticin family and their receptor types in health and diseases is critical to develop novel therapeutic strategies with safety concerns. ▪